Cargando…

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study

BACKGROUND: Optimal adherence to imatinib therapy is of paramount importance to maximise treatment effectiveness in patients with chronic myeloid leukaemia (CML). The main objective of this study was to investigate patient-reported personal factors associated with adherence behaviour. METHODS: Analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Efficace, F, Baccarani, M, Rosti, G, Cottone, F, Castagnetti, F, Breccia, M, Alimena, G, Iurlo, A, Rossi, A R, Pardini, S, Gherlinzoni, F, Salvucci, M, Tiribelli, M, Vignetti, M, Mandelli, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464760/ https://www.ncbi.nlm.nih.gov/pubmed/22871884 http://dx.doi.org/10.1038/bjc.2012.348

Ejemplares similares

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
por: Breccia, Massimo, et al.
Publicado: (2017)

P1706: CLINICAL UTILITY OF ONLINE MONITORING OF PATIENT-REPORTED SYMPTOMS IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN REAL-LIFE PRACTICE
por: Efficace, F., et al.
Publicado: (2022)

The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study
por: Efficace, Fabio, et al.
Publicado: (2021)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
por: Castagnetti, Fausto, et al.
Publicado: (2021)

Treatment Recommendations for Chronic Myeloid Leukemia
por: Baccarani, Michele, et al.
Publicado: (2014)

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
por: Martinelli, Giovanni, et al.
Publicado: (2007)

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia
por: Gugliotta, Gabriele, et al.
Publicado: (2017)

Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
por: Luciano, Luigia, et al.
Publicado: (2023)

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
por: Iurlo, A., et al.
Publicado: (2023)

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment
por: Russo, D, et al.
Publicado: (2015)

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
por: Breccia, Massimo, et al.
Publicado: (2020)

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
por: Gugliotta, Gabriele, et al.
Publicado: (2022)

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
por: Soverini, Simona, et al.
Publicado: (2019)

Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia
por: Latagliata, Roberto, et al.
Publicado: (2016)

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy
por: Luatti, Simona, et al.
Publicado: (2017)

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients
por: Ricciardi, Maria Rosaria, et al.
Publicado: (2018)

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
por: Annunziata, Mario, et al.
Publicado: (2020)

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
por: Soverini, Simona, et al.
Publicado: (2016)

Current treatment approaches in CML
por: Castagnetti, Fausto, et al.
Publicado: (2019)

Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
por: Baccarani, Michele, et al.
Publicado: (2022)

Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine
por: Breccia, M., et al.
Publicado: (2022)

EORTC QLU-C10D value sets for Austria, Italy, and Poland
por: Gamper, E. M., et al.
Publicado: (2020)

Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study
por: Malagola, Michele, et al.
Publicado: (2021)

Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study
por: Iurlo, Alessandra, et al.
Publicado: (2022)

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors
por: Mancini, M., et al.
Publicado: (2019)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
por: Iurlo, Alessandra, et al.
Publicado: (2021)

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
por: Soverini, Simona, et al.
Publicado: (2016)

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
por: Steegmann, J L, et al.
Publicado: (2016)

Fatigue of newly diagnosed patients with acute myeloid leukemia: comparison to the general population and investigation of predictive factors
por: Oswald, Laura B., et al.
Publicado: (2021)

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome
por: Iurlo, Alessandra, et al.
Publicado: (2016)

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib
por: Breccia, Massimo, et al.
Publicado: (2008)

Residual Peripheral Blood CD26(+) Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
por: Bocchia, Monica, et al.
Publicado: (2018)

Systematic review of dasatinib in chronic myeloid leukemia
por: Breccia, Massimo, et al.
Publicado: (2013)

Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy
por: Borghi, Lidia, et al.
Publicado: (2021)

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
por: Breccia, Massimo, et al.
Publicado: (2023)

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation
por: Dragani, Matteo, et al.
Publicado: (2020)

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
por: Fava, Carmen, et al.
Publicado: (2019)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
por: Hochhaus, A, et al.
Publicado: (2016)

Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy
por: Efficace, Fabio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a88otqjjk3jplcknorpbmpmfdf